Archives

Use the basic search or click on advanced for more search options.

Advanced Search Basic Search Advanced Search

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-10-15
    E.g., 2018-10-15

Archive Search

1 results
10:49 AM, May 11, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Arcus reports Phase I safety data for cancer candidate AB928

in a Phase I trial showing that single and multiple ascending doses of cancer candidate AB928
Chicago. The company plans to report final data from the double-blind, placebo-controlled trial in mid-2018. AB928
ADORA2A) and ADORA2B antagonist. Arcus also plans to start Phase I/Ib testing in mid-2018 of AB928